[Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous  Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma].
BACKGROUND
A great individual differences to chemotherapeutic effects existed in the patient with advanced lung cancer. How to choose the optimum regimens to achieve the individuation and maximum effect of chemotherapy for lung cancer is worth exploring. The study was designed to examine the effect of ex vitro chemo-sensitivity assay in xeno-free culture of autologous malignant effusion cells from patients with advanced lung adenocarcinoma.


METHODS
The 50 treatment-naive patients with lung adenocarcinoma complicated with malignant pleural or pericardial effusions were enrolled. Effusions of all cases had been controlled by closed drainage and 300 mL-500 mL of which were retained under sterile condition from 25 cases (Chemo-sensitivity group). Primary malignant effusion cells were isolated from autologous effusions of the patients. Then, xeno-free culture (average 11 days) were intervened with 8 chemotherapeutic drugs commonly used in clinical practice and were determined by CCK-8 assay. Optimum regimens were selected for chemotherapy based on the results of chemosensitivity test. As a contrast, chemotherapy regimens for the other 25 patients (Control group) were on the basis of physician's clinical experience.


RESULTS
After four cycles of chemotherapy, in Chemo-sensitivity group, 17 (68.0%) cases were determined for partial response (PR), 5 (20.0%) cases for stable disease (SD), and the objective response rate (ORR) was 68.0%, the disease control rate (DCR) was 88.0%. Meanwhile, in Control group, 9 (36.0%) cases were determined for PR, 7 (28.0%) cases for SD, and, the ORR was 36.0%, the DCR was 64.0%. There were significant differences between the two groups in ORR and DCR (P<0.05). To the end of follow-up, there were 21 cases of death in Chemo-sensitivity group as well as 22 cases in Control group. The mean progression-free survival (PFS) in Chemo-sensitivity group and Control group respectively were 10.0 months and 5.8 months, and the mean overall survival (OS) in the two groups were 30.2 months and 21.2 months respectively. There were also significant differences between the two groups in PFS and OS (P<0.05). Furthermore, the adverse reactions in both groups were mild and controllable.


CONCLUSIONS
Xeno-free culture of autologous malignant effusion cells from patients with advanced lung adenocarcinoma and ex vitro chemo-sensitivity assay are beneficial to the rational choices of chemotherapeutic agents used in patients with lung adenocarcinoma complicated with malignant effusions, which is a worthy trial in personalized cell culture for individualized cancer therapy and further studies.
Department of Emergency, Shanghai Chest Hospital,  Shanghai Jiaotong University, Shanghai 200030, China.
Liang
L
Chen
Department of Nuclear Medicine, Shanghai Chest Hospital,  Shanghai Jiaotong University, Shanghai 200030, China.
Shunfang
S
Yang
Department of Emergency, Shanghai Chest Hospital,  Shanghai Jiaotong University, Shanghai 200030, China.
Jinqi
J
Jiang
Department of Emergency, Shanghai Chest Hospital,  Shanghai Jiaotong University, Shanghai 200030, China.
Ying
Y
Zhang
Department of Emergency, Shanghai Chest Hospital,  Shanghai Jiaotong University, Shanghai 200030, China.
Hui
H
Feng
Department of Nuclear Medicine, Shanghai Chest Hospital,  Shanghai Jiaotong University, Shanghai 200030, China.
Jie
J
Cao
Department of Laboratory, Shanghai Chest Hospital,  Shanghai Jiaotong University, Shanghai 200030, China.
Xinyue
X
Ge
Department of Nuclear Medicine, Shanghai Chest Hospital,  Shanghai Jiaotong University, Shanghai 200030, China.
Wenhui
W
Xie
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000166:cytology* / Q000188:drug therapy / Q000401:mortality; D015996:Survival Rate; D014407:Tumor Cells, Cultured / Q000187:drug effects*
D000970:Antineoplastic Agents; D002945:Cisplatin
Zhongguo Fei Ai Za Zhi. 2009 Oct 20;12(10):1055-60
20723342
Cancer Chemother Pharmacol. 2007 Mar;59(4):507-13
16896928
Ann Transl Med. 2014 Oct;2(10):97
25405151
Biomed Pharmacother. 2007 Oct;61(9):562-5
17913448
PLoS One. 2014 Sep 30;9(9):e108941
25268124
Zhongguo Fei Ai Za Zhi. 2009 Jul 20;12(7):753-9
20719150
Anticancer Res. 2005 Sep-Oct;25(5):3453-9
16101163
Pneumonol Alergol Pol. 2010;78(6):407-17
21077033
Zhongguo Fei Ai Za Zhi. 2011 Feb;14(2):79-85
21342638
World J Gastroenterol. 2008 May 21;14(19):3064-8
18494060
Sci Transl Med. 2015 Jul 29;7(298):298ra118
26223301